NEWTOWN, PA — Helius Medical Technologies, Inc. (NASDAQ: HSDT) announced encouraging results from its PoNSTEP study, ...

Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced that Aetna Healthcare has authorized a claim for reimbursement for ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...

CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers ...

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius Medical Technologies will present significant new study results at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting, showcasing the sustained efficacy of its PoNS® device.

Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $2.2 million, announced today that United Healthcare has approved reimbursement for the Portable ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement NEWTOWN, Pa., May 12, 2025 (GLOBE ...

today announced a reimbursement approval for the PoNS Device from a second major healthcare provider, United Healthcare. “This additional claim approval and reimbursement from a second major ...